Ace­to keeps up spend­ing spree with ac­qui­si­tion of Ire­land's A&C

Last April, when Ace­to ac­quired Biore­agent, CEO Gilles Cot­ti­er wasn’t able to greet any of his new col­leagues in per­son. But Tues­day, 18 months and four ac­qui­si­tions lat­er, he was in Ire­land, meet­ing mem­bers of the A&C Bio Buffer, just as his com­pa­ny an­nounced it bought out the CMO.

Gilles Cot­ti­er

The New York-based man­u­fac­tur­er ac­quired A&C Bio Buffer to help boost its Covid-19 re­lief ef­forts and ex­pand its wingspan with­in man­u­fac­tur­ing, the com­pa­ny an­nounced Tues­day.

A&C man­u­fac­tures bi­o­log­i­cal buffers — which are an or­gan­ic sub­stance that main­tains a con­stant pH lev­el — process and clean­ing so­lu­tions, and wa­ter for in­jec­tion at its Lim­er­ick, Ire­land site. It’s the sixth ac­qui­si­tion Ace­to has made in the past 2 years. The move comes just months af­ter Ace­to picked up A&C group, which A&C Bio Buffer was for­mer­ly a part of. And though Cot­ti­er is not ready to dis­close just what the com­pa­ny’s next moves are, it isn’t done with merg­ers and ac­qui­si­tions just yet.

Fi­nan­cial terms of the deal were not dis­closed.

“We are proud of A&C Bio Buffer’s out­stand­ing rep­u­ta­tion for qual­i­ty and cus­tomer ser­vice, and its emer­gence as a lead­ing spe­cial­ty man­u­fac­tur­er of GMP cus­tom buffers and chem­i­cal blend prod­ucts for the bio­phar­ma­ceu­ti­cal in­dus­try,” A&C CEO John God­frey said in a press re­lease. “We are de­light­ed that our unique ca­pa­bil­i­ties, Eu­ro­pean foot­print and cus­tom prod­ucts are be­ing in­cor­po­rat­ed in­to Acute, as we con­tin­ue our evo­lu­tion as a dy­nam­ic new so­lu­tions provider to the glob­al phar­ma­ceu­ti­cal sec­tor.”

The com­pa­ny has been grow­ing quick­ly, while play­ing a key role in sup­ply­ing raw ma­te­ri­als for the Covid-19 vac­cines.

In June, Ace­to an­nounced that it ac­quired Cas­cade Chem­istry, a Eu­gene, Ore­gon-based CD­MO that makes ac­tive phar­ma­ceu­ti­cal in­gre­di­ents. In May, Ace­to ac­quired Fi­nar Lim­it­ed, a New York dis­trib­u­tor, and Biore­agent in April. In De­cem­ber 2020 it took on IsleChem and its con­tract R&D an­a­lyt­i­cal ser­vices. The ac­qui­si­tions add to its al­ready-es­tab­lished man­u­fac­tur­ing op­er­a­tions in Chi­na, In­dia and Eu­rope, in ad­di­tion to North Amer­i­ca.

While that growth will not go on for­ev­er, it is cer­tain­ly here now, and Ace­to has set it­self up to be a key play­er in vac­ci­na­tion ef­forts.

“Each of these dif­fer­ent com­pa­nies is a dif­fer­ent build­ing block, some are more small mol­e­cule ori­ent­ed,” Cot­ti­er said in an in­ter­view with End­points News. “A&C is re­al­ly a crit­i­cal part for up­stream and down­stream for the bio­phar­ma in­dus­try. “

The Big Phar­ma dis­card pile; Lay­offs all around while some biotechs bid farewell; New Roche CEO as­sem­bles top team; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

With earnings seasons in full swing, we’ve listened in on all the calls so you don’t have to. But news is popping up from all corners, so make sure you check out our other updates, too.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 158,500+ biopharma pros reading Endpoints daily — and it's free.

Raymond Stevens, Structure Therapeutics CEO

Be­hind Fri­day's $161M IPO: A star sci­en­tist, GPCR drug dis­cov­ery and a plan to chal­lenge phar­ma in di­a­betes

What does it take to pull off a $161 million biotech IPO these days?

In Structure Therapeutics’ case, it means having a star scientist co-founder paired with the computational drug discovery company Schrödinger, $198 million in private funding from blue-chip investors, almost six years of research work on G protein-coupled receptors and a slate of oral, small-molecule drugs, with an eye on the huge and growing diabetes and weight-loss market.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 158,500+ biopharma pros reading Endpoints daily — and it's free.

Sen. Ron Wyden (D-OR) (Francis Chung/E&E News/Politico via AP Images)

In­fla­tion re­bates in­com­ing: Wyden calls on CMS to move quick­ly as No­var­tis CEO pledges re­ver­sal

Senate Finance Chair Ron Wyden (D-OR) this week sent a letter to the head of the Centers for Medicare & Medicaid Services seeking an update on how and when new inflation-linked rebates will take effect for drugs that see major price spikes.

The newly signed Inflation Reduction Act requires manufacturers to pay a rebate to Medicare when they increase drug prices faster than the rate of inflation.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 158,500+ biopharma pros reading Endpoints daily — and it's free.

Trodelvy notch­es a win in most com­mon form of breast can­cer

Following a promise last year to go “big and fast in breast cancer,” Gilead has secured a win for Trodelvy in the most common form.

The drug was approved to treat HR-positive, HER2-negative breast cancer patients who’ve already received endocrine-based therapy and at least two other systemic therapies for metastatic cancer, Gilead announced on Friday.

Trodelvy won its first indication in metastatic triple-negative breast cancer back in 2020, and has since added urothelial cancer to the list. HR-positive HER2-negative breast cancer accounts for roughly 70% of new breast cancer cases worldwide per year, according to senior VP of oncology clinical development Bill Grossman, and many patients develop resistance to endocrine-based therapies or worsen on chemotherapy.

Af­ter 13 years, Ramy Mah­moud steps in­to CEO seat at Opti­nose; Ru­pert Vessey set to ex­it Bris­tol My­ers in Ju­ly

After 13 years as president and COO at Optinose, Ramy Mahmoud has stepped into a new role as its CEO. He is taking the place of Peter Miller, who stepped down earlier this week, though Miller is still staying with the company as a consultant.

In 2010, the two business partners joined Optinose to take it in a new direction, transforming it from a delivery platform to product company. They previously worked together at Johnson & Johnson, when Miller was president at Janssen and Mahmoud headed medical affairs. Miller said after he learned about Optinose, “I did what I always do, which is find people smarter than me to talk with about the idea. And the first person I called was Ramy … and I said, ‘Hey, Ramy, what do you think of this technology?’”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 158,500+ biopharma pros reading Endpoints daily — and it's free.

Ma­gen­ta halts stem cell work and may sell it­self fol­low­ing pa­tient death, clin­i­cal hold

Magenta Therapeutics said it is halting work on its stem cell transplant drug pipeline and may sell itself, a week after the company reported the death of a patient in an early stage trial of its antibody-drug conjugate.

The Cambridge, MA-based company said it will conduct a “review of strategic alternatives,” and that could include an “acquisition, merger, business combination, or other transaction.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 158,500+ biopharma pros reading Endpoints daily — and it's free.

Goldfinch Bio CEO Tony Johnson (L) and Karuna Therapeutics CEO Bill Meury

Karuna li­cens­es Goldfinch as­sets to com­pete with Boehringer In­gel­heim in neu­ro­science

Karuna Therapeutics is looking to compete with Boehringer Ingelheim on depression and anxiety with a new license to Goldfinch Bio’s assets, starting with $15 million to the shuttered biotech.

Karuna steps into an arena already being tested by Boehringer in multiple Phase II studies — the two are targeting transient receptor potential canonical 4 and 5, or TRPC4/5, which is thought to have a role in neuroscience indications. Goldfinch’s asset went through a Phase II in kidney diseases, but Karuna’s sights are set on mood and anxiety disorders for now.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 158,500+ biopharma pros reading Endpoints daily — and it's free.

Te­va drops out of in­dus­try trade group PhRMA

Following in AbbVie’s footsteps, Teva confirmed on Friday that it’s dropping out of the industry trade group Pharmaceutical Research and Manufacturers of America (PhRMA).

Teva didn’t give a reason for its decision to leave, saying only in a statement to Endpoints News that it annually reviews “effectiveness and value of engagements, consultants and memberships to ensure our investments are properly seated.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 158,500+ biopharma pros reading Endpoints daily — and it's free.

Sanofi CFO Jean-Baptiste de Chatillon (L) and CEO Paul Hudson (Romuald Meigneux/Sipa via AP Images)

Sanofi sees downtick in flu sales as it preps for launch of RSV an­ti­body

Sanofi expects its RSV antibody jointly developed with AstraZeneca will be available next season, executive VP of vaccines Thomas Triomphe announced on the company’s quarterly call.

Beyfortus, also known as nirsevimab, was approved in the EU back in November and is currently under FDA review with an expected decision coming in the third quarter of this year. The news comes as the FDA plans to hold advisory committee meetings over the next couple months to review RSV vaccines from Pfizer and GSK.